Amicus Therapeutics, Inc. (FOLD) has a negative trailing P/E of -164.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 44.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.61%, forward earnings yield 2.27%. PEG 0.88 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.3 | -0.14 | 1.85 | 134.73 | - |
| 2017 | -7.8 | -0.32 | 6.25 | 59.76 | - |
| 2018 | -5.1 | -3.14 | 5.19 | 19.51 | - |
| 2019 | -6.6 | 0.31 | 4.92 | 12.85 | - |
| 2020 | -21.6 | 0.78 | 20.87 | 22.91 | - |
| 2021 | -12.5 | 0.89 | 10.20 | 10.26 | - |
| 2022 | -14.9 | 1.37 | 28.68 | 10.72 | - |
| 2023 | -27.6 | 0.73 | 26.15 | 10.49 | - |
| 2024 | -51.1 | 0.79 | 14.78 | 5.43 | - |
| 2025 | -162.0 | 3.17 | 16.01 | 6.92 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.49 | $4.96M | $-200.04M | -4034.7% |
| 2017 | $-1.85 | $36.93M | $-284M | -769% |
| 2018 | $-1.88 | $91.25M | $-349M | -382.5% |
| 2019 | $-1.48 | $182.24M | $-356.39M | -195.6% |
| 2020 | $-1.07 | $260.89M | $-276.85M | -106.1% |
| 2021 | $-0.92 | $305.51M | $-250.46M | -82% |
| 2022 | $-0.82 | $329.23M | $-236.57M | -71.9% |
| 2023 | $-0.51 | $399.36M | $-151.58M | -38% |
| 2024 | $-0.18 | $528.3M | $-56.11M | -10.6% |
| 2025 | $-0.09 | $634.21M | $-27.11M | -4.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.31 | $0.31 – $0.32 | $749.83M | $747.8M – $751.02M | 2 |
| 2027 | $0.60 | $0.58 – $0.64 | $893.2M | $867.04M – $912.27M | 4 |
| 2028 | $0.91 | $0.75 – $1.05 | $1.09B | $1.08B – $1.09B | 4 |
| 2029 | $1.36 | $1.32 – $1.40 | $1.31B | $1.28B – $1.34B | 2 |
| 2030 | $1.67 | $1.62 – $1.72 | $1.47B | $1.44B – $1.5B | 2 |
